Silke Gloaguen

Statistics

Publications

Citations

347

H-Index

Active since

2015

Affiliations

Marien Hospital Düsseldorf(Current)

Hôpital Saint-Louis

Groupe Francophone des Myélodysplasies

Assistance Publique – Hôpitaux de Paris

Université Paris Cité

Silke Gloaguen is an author at Marien Hospital Düsseldorf specializing in medicine, hematologic malignancy pharmacotherapy, and hematologic malignancy therapy.

Publications per year

2015–2023

Publications

Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials

Uwe Platzbecker, Pierre Fenaux, Lionel Adès et al. · Blood · 2018 · 178 citations · Full text

Medicine, Hematology, Internal Medicine +12

Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network

Raphaël Itzykson, Valeria Santini, Sylvain Thépot et al. · Journal of Clinical Oncology · 2022 · 47 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Path-dependence, lock-in, and student perceptions of nuclear energy in France: Implications from a pilot study

Roh Pin Lee, Silke Gloaguen · Energy Research & Social Science · 2015 · 37 citations · Full text

Engineering, Higher Education, Nuclear Engineering +9

Decitabine Versus Hydroxyurea for Advanced Proliferative CMML: Results of the Emsco Randomized Phase 3 Dacota Trial

Raphaël Itzykson, Valeria Santini, Cendrine Chaffaut et al. · Blood · 2020 · 29 citations

Medicine, Oncology, Pharmacology +7

Enasidenib (ENA) Is Effective in Patients with IDH2 Mutated Myelodysplastic Syndrome (MDS) : The Ideal Phase 2 Study By the GFM Group

Lionel Adès, Sophie Dimicoli‐Salazar, Marie Sébert et al. · Blood · 2021 · 22 citations

Medicine, Hematology, Oncology +8

1–5 of 7